Skip to main content
. 2020 Aug 24;30(8):1263–1271. doi: 10.1007/s00787-020-01614-4

Table 2.

Predictors of BMI z-score in children and adolescents during antipsychotic treatment

 < 15 weeks follow-upa 15–52 weeks follow-upa  > 52 weeks follow-upa
β p value SE 95% CI β p value SE 95% CI β p value SE 95% CI
Model 1
 Dose equivalent/kg 0.27  < 0.001 0.06 0.16 to 0.38 0.55 0.316 0.05 − 0.05 to 0.16 − 0.05 0.307 0.05 − 0.14 to 0.04
 Duration of use (weeks) 0.03  < 0.001 0.00 0.03 to 0.04 0.01 0.088 0.00 0.00 to 0.02 0.00  < 0.001 0.00 0.00 to 0.00
 Baseline BMI z score 0.92  < 0.001 0.02 0.90 to 0.96 0.80  < 0.001 0.05 0.7 to 0.9 0.69  < 0.001 0.07 0.56 to 0.83
 Age (years) 0.00 0.661 0.00 0.00 to 0.00 0.00 0.507 0.00 0.00 to 0.00 0.00 0.457 0.00 0.00 to 0.00
 Sex (male) 0.10 0.076 0.06 − 0.01 to 0.22 0.27 0.096 0.16 − 0.05to 0.60 0.22 0.328 0.22 − 0.22 to 0.66
 Antipsychotic
  Risperidone 0.07 0.197 0.05 − 0.04 to 0.18 0.16 0.309 0.15 − 0.14 to 0.45 − 0.07 0.756 0.22 − 0.50 to 0.36
  Aripiprazole − 0.03 0.401 0.07 − 0.17 to 0.12 0.05 0.814 0.20 − 0.35 to 0.45 0.16 0.950 0.26 − 0.49 to 0.52
  Pipamperone − 0.07 0.255 0.06 − 0.19 to 0.05 − 0.26 0.155 0.18 − 0.61 to 0.10 0.08 0.762 0.26 − 0.43 to 0.59
 No previous antipsych. treatment 0.11 0.026 0.05 0.01 to 0.21 0.16 0.273 0.14 − 0.12 to 0.43 0.13 0.524 0.20 − 0.27 to 0.53
 Psychiatric classification
  ASS − 0.01 0.913 0.07 − 0.15 to 0.14 0.06 0.804 0.23 − 0.39 to 0.50 0.27 0.328 0.27 − 0.27 to 0.80
  ADHD − 0.01 0.786 0.05 − 0.12 to 0.09 0.02 0.905 0.15 − 0.27 to 0.31 0.23 0.249 0.20 − 0.16 to 0.62
  Other psychiatric class 0.03 0.596 0.05 − 0.08 to 0.14 − 0.15 0.339 0.15 − 0.45 to 0.15 − 0.10 0.630 0.20 − 0.49 to 0.29
 Somatic diagnosis
  Epilepsy − 0.10 0.318 0.10 − 0.29 to 0.09 − 0.16 0.534 0.26 − 0.66 to 0.34 − 0.48 0.115 0.31 − 1.08 to 0.12
  Other − 0.05 0.325 0.05 − 0.15 to 0.05 − 0.01 0.924 0.14 − 0.28 to 0.26 0.16 0.412 0.19 − 0.21 to 0.53
 Concomitant medication
  No stimulant 0.13 0.040 0.06 0.00 to 0.25 0.38 0.007 0.14 − 0.11 to 0.66 0.43  < 0.001 0.10 0.24 to 0.62
  No other medication 0.09 0.267 0.08 − 0.07 to 0.25 0.12 0.543 0.22 − 0.31 to 0.55 0.01 0.948 0.16 − 0.30 to 0.32
 Ethnicity (Dutch) − 0.04 0.709 0.06 − 0.16 to 0.08 0.03 0.842 0.16 − 0.29 to 0.35 0.27 0.285 0.25 − 0.24 to 0.79
 Sport − 0.05 0.310 0.05 − 0.15 to 0.05 0.01 0.949 0.15 − 0.28 to 0.30 − 0.10 0.616 0.20 − 0.48 to 0.29
 IQ < 70 0.01 0.829 0.06 − 0.10 to 0.12 0.04 0.779 0.14 − 0.24 to 0.32 − 0.22 0.261 0.20 − 0.61 to 0.16
Model 2
 Dose equivalent/kg − 0.05 0.518 0.08 − 0.21 to 0.11 0.01 0.947 0.17 − 0.31 to 0.34 − 0.08 0.079 0.05 − 0.17 to 0.01
  × Duration of use (weeks) 0.02 0.011 0.01 0.01 − 0.04 0.00 0.792 0.00 − 0.01 to 0.01 0.00 0.880 0.00 0.00 to 0.00
 Baseline BMI z score 1.00  < 0.001 0.02 0.96 − 1.04 0.85  < 0.001 0.11 0.63 to 1.06 0.68  < 0.001 0.07 0.53 to 0.82
  × Duration of use (weeks) − 0.01  < 0.001 0.00 − 0.02 to 0.01 0.00 0.667 0.00 − 0.01 to 0.01 0.00 0.695 0.00 0.00 to 0.00
 Sex (male) 0.07 0.284 0.07 − 0.06 − 0.2 0.16 0.695 0.40 − 0.63 to 0.94 0.29 0.221 0.24 − 0.17 to 0.75
  × Duration of use (weeks) 0.01 0.264 0.01 − 0.01 to 0.02 0.00 0.04 0.01 − 0.02 to 0.03 0.00 0.623 0.00 0.00 to 0.00
 No previous antipsych. Drug 0.02 0.688 0.06 − 0.09 to 1.14 0.10 0.31 0.746 − 0.5 to 0.7 0.23 0.262 0.21 − 0.17 to 0.64
  × Duration of use (weeks) 0.02 0.018 0.01 0.00 to 0.03 0.00 0.859 0.01 − 0.02 to 0.02 0.00 0.141 0.00 0.00 to 0.00
 No stimulant 0.16 0.033 0.07 0.01 to 0.30 0.49 0.114 0.31 − 0.12 to 1.10 0.17 0.259 0.15 − 0.13 to 0.48
  × Duration of use (weeks) 0.00 0.915 0.00 − 0.02 to 0.02 0.00 0.722 0.01 − 0.02 to 0.02 0.00 0.201 0.00 0.00 to 0.00

Antipsych antipsychotic, Class classification, SE standard error, 95% CI 95% confidence interval

a < 15 weeks: n = 144 patients, 15–52 weeks 111 patients, > 52 weeks: 58 patients